The pharmaceutical rebate system was not designed. It accumulated. Over three decades of regulatory responses, bilateral contractual innovations, and competitive dynamics among manufacturers, pharmacy benefit managers, and plan sponsors, a set of incentive structures emerged that now functions with the coherence of intentional architecture — while evading the accountability that intentional design would invite. The Congressional Budget Office has estimated that rebates and other price concessions from manufacturers to PBMs and plans reduce gross drug spending by roughly thirty percent in the commercial market, a figure that obscures as much as it illuminates because the distribution of those rebates — who receives them, in what form, and at what point in the supply chain — determines their actual effect on patient costs.
Origins and Accumulation
The pharmaceutical rebate system was not designed. It accumulated. Over three decades of regulatory responses, bilateral contractual innovations, and competitive dynamics among manufacturers, pharmacy benefit managers, and plan sponsors, a set of incentive structures emerged that now functions with the coherence of intentional architecture — while evading the accountability that intentional design would invite. The Congressional Budget Office has estimated that rebates and other price concessions from manufacturers to PBMs and plans reduce gross drug spending by roughly thirty percent in the commercial market, a figure that obscures as much as it illuminates because the distribution of those rebates — who receives them, in what form, and at what point in the supply chain — determines their actual effect on patient costs.
Origins and Accumulation
The rebate mechanism’s origins lie in the early PBM era of the 1980s and 1990s, when pharmacy benefit managers were emerging as administrative intermediaries between employers and pharmacies and sought to use formulary placement — their ability to steer patient prescriptions toward preferred drugs — as leverage to extract price concessions from manufacturers. The logic was straightforward: access to a large, captive patient population has value, and manufacturers would pay for preferred formulary tier placement. Rebates were the contractual vehicle for that payment. Over time, the system became more elaborate — supplemental rebates, market-share rebates, tiering rebates, performance-based rebates — until the original formulary management function became inseparable from the financial engineering surrounding it.
What makes the system architecturally stable, and therefore reform-resistant, is that each participant’s financial model has adapted to treat the rebate flow as a structural input rather than a negotiable component. PBMs have built their margin models around the spread between list prices and net prices. Manufacturers have built their launch price strategies around the assumption that substantial rebates will be required to achieve and maintain preferred formulary status, which requires list prices to be set high enough to accommodate rebates while preserving an acceptable net revenue. Plan sponsors have organized their formulary designs around the rebate revenue they expect to receive, which in some cases offsets premium costs and in others simply flows to plan reserves. The rebate is simultaneously a manufacturer payment, a PBM revenue source, and a plan sponsor budget line.
The List Price Inflation Cycle
The structural dependence on rebates has produced a well-documented but politically unresolved dynamic: list prices rise, in part, to accommodate ever-larger rebates demanded by PBMs as a condition of formulary placement. A manufacturer that launches a new branded drug into a competitive therapeutic category faces pressure to offer rebates competitive with existing agents. If the category leader is offering a twenty percent rebate on list price to achieve preferred tier status, the entrant may need to offer twenty-five or thirty percent to displace it. But rebates are calculated as a percentage of list price, which creates an incentive to set list prices higher to generate a larger absolute rebate payment while maintaining an acceptable net revenue. The cycle is self-reinforcing: higher list prices support larger rebates, which justify higher list prices.
The patients who bear the most direct cost of this system are those in high-deductible health plans or with cost-sharing structures based on list rather than net prices. A patient in the deductible phase of a plan pays the full list price for a branded drug, while the plan receives a rebate that offsets the plan’s costs after the deductible is met. The patient’s out-of-pocket payment subsidizes the plan’s budget without the patient’s knowledge or consent. This dynamic — which CBO has analyzed in detail — is one of the more troubling distributional features of the rebate system, concentrating cost burden on the sickest patients who have the least ability to substitute to lower-cost alternatives.
Why Reform Is Hard
Every major actor in the pharmaceutical distribution system has organized its financial expectations around the rebate architecture. Dismantling it — even gradually, even with transition provisions — requires those actors to simultaneously restructure their pricing strategies, renegotiate their contractual relationships, and revise their financial projections. The coordination problem is not trivial. An individual plan sponsor or PBM that moves to net pricing unilaterally may find that its drug acquisition costs increase because manufacturers have priced their list prices to anticipate rebates that are no longer forthcoming. The collective action problem embedded in the rebate system is as important as any of its specific inequities.
What reform attempts have consistently underestimated is the degree to which the rebate system has become a mechanism for cross-subsidization within the broader healthcare financing structure. The rebate revenue that flows to plan sponsors helps offset premium costs for all enrollees, not just those using the drugs generating the rebates. Eliminating rebates without replacing their revenue function — through list price reductions, through government price-setting, or through some other mechanism — produces a distributional problem that may be more visible and politically salient than the current system’s inequities. That is not an argument against reform. It is an argument for taking the second-order effects as seriously as the first.
The rebate mechanism’s origins lie in the early PBM era of the 1980s and 1990s, when pharmacy benefit managers were emerging as administrative intermediaries between employers and pharmacies and sought to use formulary placement — their ability to steer patient prescriptions toward preferred drugs — as leverage to extract price concessions from manufacturers. The logic was straightforward: access to a large, captive patient population has value, and manufacturers would pay for preferred formulary tier placement. Rebates were the contractual vehicle for that payment. Over time, the system became more elaborate — supplemental rebates, market-share rebates, tiering rebates, performance-based rebates — until the original formulary management function became inseparable from the financial engineering surrounding it.
What makes the system architecturally stable, and therefore reform-resistant, is that each participant’s financial model has adapted to treat the rebate flow as a structural input rather than a negotiable component. PBMs have built their margin models around the spread between list prices and net prices. Manufacturers have built their launch price strategies around the assumption that substantial rebates will be required to achieve and maintain preferred formulary status, which requires list prices to be set high enough to accommodate rebates while preserving an acceptable net revenue. Plan sponsors have organized their formulary designs around the rebate revenue they expect to receive, which in some cases offsets premium costs and in others simply flows to plan reserves. The rebate is simultaneously a manufacturer payment, a PBM revenue source, and a plan sponsor budget line.
The List Price Inflation Cycle
The structural dependence on rebates has produced a well-documented but politically unresolved dynamic: list prices rise, in part, to accommodate ever-larger rebates demanded by PBMs as a condition of formulary placement. A manufacturer that launches a new branded drug into a competitive therapeutic category faces pressure to offer rebates competitive with existing agents. If the category leader is offering a twenty percent rebate on list price to achieve preferred tier status, the entrant may need to offer twenty-five or thirty percent to displace it. But rebates are calculated as a percentage of list price, which creates an incentive to set list prices higher to generate a larger absolute rebate payment while maintaining an acceptable net revenue. The cycle is self-reinforcing: higher list prices support larger rebates, which justify higher list prices.
The patients who bear the most direct cost of this system are those in high-deductible health plans or with cost-sharing structures based on list rather than net prices. A patient in the deductible phase of a plan pays the full list price for a branded drug, while the plan receives a rebate that offsets the plan’s costs after the deductible is met. The patient’s out-of-pocket payment subsidizes the plan’s budget without the patient’s knowledge or consent. This dynamic — which CBO has analyzed in detail — is one of the more troubling distributional features of the rebate system, concentrating cost burden on the sickest patients who have the least ability to substitute to lower-cost alternatives.
Why Reform Is Hard
Every major actor in the pharmaceutical distribution system has organized its financial expectations around the rebate architecture. Dismantling it — even gradually, even with transition provisions — requires those actors to simultaneously restructure their pricing strategies, renegotiate their contractual relationships, and revise their financial projections. The coordination problem is not trivial. An individual plan sponsor or PBM that moves to net pricing unilaterally may find that its drug acquisition costs increase because manufacturers have priced their list prices to anticipate rebates that are no longer forthcoming. The collective action problem embedded in the rebate system is as important as any of its specific inequities.
What reform attempts have consistently underestimated is the degree to which the rebate system has become a mechanism for cross-subsidization within the broader healthcare financing structure. The rebate revenue that flows to plan sponsors helps offset premium costs for all enrollees, not just those using the drugs generating the rebates. Eliminating rebates without replacing their revenue function — through list price reductions, through government price-setting, or through some other mechanism — produces a distributional problem that may be more visible and politically salient than the current system’s inequities. That is not an argument against reform. It is an argument for taking the second-order effects as seriously as the first.
